19 November 2021
Latham & Watkins Advises BridgeBio Pharma in US$750 Million Non-Dilutive Debt Financing
Advising firms
Deal team
14 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Haim Zaltzman Lead | Latham & Watkins LLP | Partner | Not stated | Bay Area |
| Dan Van Fleet Lead | Latham & Watkins LLP | Partner | Not stated | Bay Area |
| Ramin Montazeri | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Tony Noh | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Reza Mojtabaee-Zamani | Latham & Watkins LLP | Partner | public company financing matters | New York |
| Jack Neff | Latham & Watkins LLP | Associate | public company financing matters | Not stated |
| Chad Jennings | Latham & Watkins LLP | Associate | regulatory matters | Not stated |
| Eric Cho | Latham & Watkins LLP | Partner | tax matters | Los Angeles |
| Mario Moreno | Latham & Watkins LLP | Associate | tax matters | Not stated |
| James Chesterman | Latham & Watkins LLP | Partner | UK finance matters | London |
| Hafza Hussein | Latham & Watkins LLP | Associate | UK finance matters | Not stated |
| Nabil Sabki | Latham & Watkins LLP | Partner | investment funds regulatory matters | Chicago |
| Jina Yun | Latham & Watkins LLP | Associate | investment funds regulatory matters | Not stated |
| Christopher Clark | Latham & Watkins LLP | Associate | corporate matters | Not stated |
Stated terms
- Stated value
- USD 750m (US$750 million)
- What the figure measures
- Facility amount
- Client
- BridgeBio PharmaBorrower
- Counterparties
- syndicate of lenders (Lenders)